Korean J Gastroenterol.  2020 Aug;76(2):60-64. 10.4166/kjg.2020.76.2.60.

Diagnosis and Severity Assessment of Alcohol-Related Liver Disease

• Kim E
• Park SH

• KMID: 2505810
• DOI: http://doi.org/10.4166/kjg.2020.76.2.60

Abstract

A diagnosis of alcohol-related liver disease (ALD) requires information on the history of excessive alcohol consumption (averageintake of 40 g or more in men and 20 g or more in women a day). Furthermore, blood tests, such as GGT, AST, ALT, and mean corpuscularvolume, and imaging studies, including abdominal ultrasound or transient elastography, are also useful. A liver biopsycan be useful for confirming the diagnosis and has prognostic value. ALD includes alcoholic fatty liver, alcoholic hepatitis, and alcoholiccirrhosis, and in most cases, clinical manifestations can overlap. The prognostic scoring systems of ALD are limited mainlyto alcoholic hepatitis, and the early mortality and treatment response can be predicted using various scoring systems. This reviewsummarizes how to diagnose and evaluate the severity of ALD in clinical practice.

Keyword

Liver diseases, alcoholic; Hepatitis, alcoholic; Diagnosis; Prognosis

Reference

1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. 2019; Burden of liver diseases in the world. J Hepatol. 70:151–171. DOI: 10.1016/j.jhep.2018.09.014. PMID: 30266282.

2. Korean Association for the Study of the Liver (KASL). 2013; KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol. 19:216–254. DOI: 10.3350/cmh.2013.19.3.216. PMID: 24133661. PMCID: PMC3796673.

3. Becker U, Deis A, Sørensen TI, et al. 1996; Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 23:1025–1029. DOI: 10.1002/hep.510230513. PMID: 8621128.

4. McQuade WH, Levy SM, Yanek LR, Davis SW, Liepman MR. 2000; Detecting symptoms of alcohol abuse in primary care settings. Arch Fam Med. 9:814–821. DOI: 10.1001/archfami.9.9.814. PMID: 11031387.

5. 2018. Nov. 14. Drinking damage prevention action plan 2018. [Internet]. Korea Ministry of Health & Welfare;Sejong: Available from: http://www.mohw.go.kr/react/modules/download.jsp?.BOARD_ID=140&CONT_SEQ=346622&FILE_SEQ=241320. cited 2020 Jun 20.

6. Puukka K, Hietala J, Koivisto H, Anttila P, Bloigu R, Niemelä O. 2006; Additive effects of moderate drinking and obesity on serum gamma-glutamyl transferase activity. Am J Clin Nutr. 83:1351–1449. DOI: 10.1093/ajcn/83.6.1351. PMID: 16789344.

7. Gough G, Heathers L, Puckett D, et al. 2015; The utility of commonly used laboratory tests to screen for excessive alcohol use in clinical practice. Alcohol Clin Exp Res. 39:1493–1500. DOI: 10.1111/acer.12780. PMID: 26110815. PMCID: PMC4515204.

8. Rinck D, Frieling H, Freitag A, et al. 2007; Combinations of carbohydratedeficient transferrin, mean corpuscular erythrocyte volume, gamma-glutamyltransferase, homocysteine and folate increase the significance of biological markers in alcohol dependent patients. Drug Alcohol Depend. 89:60–65. DOI: 10.1016/j.drugalcdep.2006.11.022. PMID: 17234365.

9. Nanji AA, French SW, Mendenhall CL. 1989; Serum aspartate aminotransferase to alanine aminotransferase ratio in human and experimental alcoholic liver disease: relationship to histologic changes. Enzyme. 41:112–115. DOI: 10.1159/000469062. PMID: 2707213.

10. Hock B, Schwarz M, Domke I, et al. 2005; Validity of carbohydratedeficient transferrin (%CDT), gamma-glutamyltransferase (gammaGT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction. 100:1477–1486. DOI: 10.1111/j.1360-0443.2005.01216.x. PMID: 16185209.

11. Nyblom H, Berggren U, Balldin J, Olsson R. 2004; High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol. 39:336–339. DOI: 10.1093/alcalc/agh074. PMID: 15208167.

12. Poynard T, Aubert A, Bedossa P, et al. 1991; A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology. 100(5 Pt 1):1397–1402. DOI: 10.1016/0016-5085(91)70030-2. PMID: 1672859.

13. Litten RZ, Bradley AM, Moss HB. 2010; Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res. 34:955–967. DOI: 10.1111/j.1530-0277.2010.01170.x. PMID: 20374219.

14. Cabarcos P, Álvarez I, Tabernero MJ, Bermejo AM. 2015; Determination of direct alcohol markers: a review. Anal Bioanal Chem. 407:4907–4925. DOI: 10.1007/s00216-015-8701-7. PMID: 25935676.

15. Zoli M, Cordiani MR, Marchesini G, et al. 1991; Prognostic indicators in compensated cirrhosis. Am J Gastroenterol. 86:1508–1513. PMID: 1928047.

16. Mueller S, Millonig G, Sarovska L, et al. 2010; Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol. 16:966–972. DOI: 10.3748/wjg.v16.i8.966. PMID: 20180235. PMCID: PMC2828601.

17. Michalak S, Rousselet MC, Bedossa P, et al. 2003; Respective roles of porto-septal fibrosis and centrilobular fibrosis in alcoholic liver disease. J Pathol. 201:55–62. DOI: 10.1002/path.1412. PMID: 12950017.

18. Afdhal NH, Bacon BR, Patel K, et al. 2015; Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 13:772–9.e93. DOI: 10.1016/j.cgh.2014.12.014. PMID: 25528010.

19. Nguyen-Khac E, Chatelain D, Tramier B, et al. 2008; Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan:prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther. 28:1188–1198. DOI: 10.1111/j.1365-2036.2008.03831.x. PMID: 18705692.

20. Levin DM, Baker AL, Riddell RH, Rochman H, Boyer JL. 1979; Nonalcoholic liver disease. Overlooked causes of liver injury in patients with heavy alcohol consumption. Am J Med. 66:429–434. DOI: 10.1016/0002-9343(79)91064-7. PMID: 433949.

21. Mueller S, Sandrin L. 2010; Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med. 2:49–67. DOI: 10.2147/HMER.S7394. PMID: 24367208. PMCID: PMC3846375.

22. Voican CS, Louvet A, Trabut JB, et al. 2017; Transient elastography alone and in combination with FibroTest^® for the diagnosis of hepatic fibrosis in alcoholic liver disease. Liver Int. 37:1697–1705. DOI: 10.1111/liv.13440. PMID: 28387018.

23. Mookerjee RP, Lackner C, Stauber R, et al. 2011; The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol. 55:1103–1111. DOI: 10.1016/j.jhep.2011.02.021. PMID: 21376092.

24. Lefkowitch JH. 2005; Morphology of alcoholic liver disease. Clin Liver Dis. 9:37–53. DOI: 10.1016/j.cld.2004.11.001. PMID: 15763228.

25. French SW. 1996; Ethanol and hepatocellular injury. Clin Lab Med. 16:289–306. DOI: 10.1016/S0272-2712(18)30270-1. PMID: 8792073.

26. Hall PD. 1994; Pathological spectrum of alcoholic liver disease. Alcohol Alcohol Suppl. 2:303–313. DOI: 10.3109/00313028509063757. PMID: 8974350.

27. Yeh MM, Brunt EM. 2007; Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 128:837–847. DOI: 10.1309/RTPM1PY6YGBL2G2R. PMID: 17951208.

28. Crabb DW, Bataller R, Chalasani NP, et al. 2016; Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia. Gastroenterology. 150:785–790. DOI: 10.1053/j.gastro.2016.02.042. PMID: 26921783. PMCID: PMC5287362.

29. Altamirano J, Miquel R, Katoonizadeh A, et al. 2014; A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology. 146:1231–9.e96. DOI: 10.1053/j.gastro.2014.03.010. PMID: 24440674. PMCID: PMC3992184.

30. Naveau S, Montembault S, Balian A, et al. 1999; Biological diagnosis of the type of liver disease in alcoholic patients with abnormal liver function tests. Gastroenterol Clin Biol. 23:1215–1224. PMID: 10617832.

31. Filingeri V, Francioso S, Sforza D, Santopaolo F, Oddi FM, Tisone G. 2016; A retrospective analysis of 1.011 percutaneous liver biopsies performed in patients with liver transplantation or liver disease:ultrasonography can reduce complications? Eur Rev Med Pharmacol Sci. 20:3609–3617.

32. Roth NC, Saberi B, Macklin J, et al. 2017; Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsy. Hepatol Commun. 1:1070–1084. DOI: 10.1002/hep4.1119. PMID: 29404443. PMCID: PMC5721404.

33. Teli MR, Day CP, Burt AD, Bennett MK, James OF. 1995; Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 346:987–990. DOI: 10.1016/S0140-6736(95)91685-7. PMID: 7475591.

34. Morgan TR, Ghany MG, Kim HY, et al. 2010; Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 52:833–844. DOI: 10.1002/hep.23744. PMID: 20564351. PMCID: PMC2932862.

35. Jonas DE, Garbutt JC, Amick HR, et al. 2012; Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 157:645–654. DOI: 10.7326/0003-4819-157-9-201211060-00544. PMID: 23007881.

36. Zatloukal K, French SW, Stumptner C, et al. 2007; From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res. 313:2033–2049. DOI: 10.1016/j.yexcr.2007.04.024. PMID: 17531973.

37. de Bruyn G, Graviss EA. 2001; A systematic review of the diagnostic accuracy of physical examination for the detection of cirrhosis. BMC Med Inform Decis Mak. 1:6. DOI: 10.1186/1472-6947-1-6. PMID: 11806763. PMCID: PMC64783.

38. Veldt BJ, Lainé F, Guillygomarc'h A, et al. 2002; Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol. 36:93–98. DOI: 10.1016/S0168-8278(01)00228-8. PMID: 11804670.

39. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. 1978; Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 75:193–199. DOI: 10.1016/0016-5085(78)90401-8. PMID: 352788.

40. Carithers RL Jr, Herlong HF, Diehl AM, et al. 1989; Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 110:685–690. DOI: 10.7326/0003-4819-110-9-685. PMID: 2648927.

41. Mathurin P, Mendenhall CL, Carithers RL Jr, et al. 2002; Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 36:480–487. DOI: 10.1016/S0168-8278(01)00289-6. PMID: 11943418.

42. Thursz MR, Richardson P, Allison M, et al. 2015; Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 372:1619–1628. DOI: 10.1056/NEJMoa1412278. PMID: 25901427.

43. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. 2006; Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial. J Hepatol. 44:784–790. DOI: 10.1016/j.jhep.2005.11.039. PMID: 16469404.

44. Dunn W, Jamil LH, Brown LS, et al. 2005; MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 41:353–358. DOI: 10.1002/hep.20503. PMID: 15660383.

45. Forrest EH, Evans CD, Stewart S, et al. 2005; Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 54:1174–1179. DOI: 10.1136/gut.2004.050781. PMID: 16009691. PMCID: PMC1774903.

46. Forrest EH, Morris AJ, Stewart S, et al. 2007; The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut. 56:1743–1746. DOI: 10.1136/gut.2006.099226. PMID: 17627961. PMCID: PMC2095721.

47. Dominguez M, Rincón D, Abraldes JG, et al. 2008; A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 103:2747–2756. DOI: 10.1111/j.1572-0241.2008.02104.x. PMID: 18721242.

48. Louvet A, Naveau S, Abdelnour M, et al. 2007; The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 45:1348–1354. DOI: 10.1002/hep.21607. PMID: 17518367.